Literature DB >> 1993555

Differential role of transforming growth factor-alpha in two human colon-carcinoma cell lines.

L F Watkins1, A E Levine.   

Abstract

Antibodies to epidermal-growth-factor receptor (EGF) and transforming growth factor-alpha (TGF-alpha) were used to determine the role of endogenous TGF-alpha in the growth of 2 human colon-carcinoma cell lines. Both the GEO and HCT 116 colon-carcinoma cell lines secrete similar levels of TGF-alpha and have similar numbers of low-affinity binding sites for EGF. However, the HCT 116 cells lack the high-affinity EGF binding site present on the GEO cells. The anti-EGF receptor antibodies effectively blocked the binding of 125I-EGF to the GEO and HCT 116 cell lines. Growth of the GEO cell line was inhibited 50-80% by the anti-EGF receptor and anti-TGF-alpha antibodies. When the same antibodies, in sufficient amounts to block binding of TGF-alpha to the cells, were added to the HCT 116 cell line, no effect on growth was seen. These results suggest that while the GEO cell line utilizes TGF-alpha in an autocrine manner, the TGF-alpha secreted by the HCT 116 cells apparently does not play a role in the growth of these cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1993555     DOI: 10.1002/ijc.2910470325

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  2 in total

1.  Metalloprotease-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor.

Authors:  J Dong; L K Opresko; P J Dempsey; D A Lauffenburger; R J Coffey; H S Wiley
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

2.  Constitutive over-expression of transforming growth factor-alpha in rat liver epithelial cells leads to increased cell cycling without transformation.

Authors:  T B Tan; P A Marino; R Padmanabhan; L L Hampton; J M Hanley-Hyde; S S Thorgeirsson
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-09       Impact factor: 2.416

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.